News

News

November 14, 2017

November ID Update

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you would like to automatically receive our monthly ID Updates by e-mail, subscribe now. NOVEMBER 2017 New Drug Approvals

October 2, 2017

October ID Update

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you would like to automatically receive our monthly ID Updates by e-mail, subscribe now. OCTOBER 2017 New Drug Approvals

September 26, 2017

Press Release – VigiLanz + The Sanford Guide

VigiLanz Becomes First Clinical Intelligence Platform to Integrate Sanford Guide Infectious Disease Content MINNEAPOLIS, MN and SPERRYVILLE, VA. – (September 26, 2017) – VigiLanz, a digital healthcare intelligence firm, and Antimicrobial Therapy Inc., publisher and developer of The Sanford Guide, announced today an exclusive partnership that brings together the market-leading clinical intelligence platform and the

September 19, 2017

September ID Update

ID Update is The Sanford Guide’s monthly summary of significant developments in the treatment of infectious diseases. Want to receive ID Update by e-mail? Click here to subscribe. We won’t spam you or share your contact information. Links marked with a “*” are accessible to Sanford Guide Web Edition and Sanford Guide All Access subscribers.

August 9, 2017

August ID Update

ID Update is The Sanford Guide’s monthly summary of significant developments in the treatment of infectious diseases. Want to receive ID Update by e-mail? Click here to subscribe. We won’t spam you or share your contact information. Links marked with a “*” are accessible to Sanford Guide Web Edition and Sanford Guide All Access subscribers.